Looking to sell Egenesis stock or options?
Egenesis is developing a gene editing and genome engineering platform aimed at revolutionizing solid organ and therapeutic cell transplantation for treating life-threatening illnesses. The company's platform provides gene editing techniques to create human-compatible organ tissue cells and spearheads programs in kidney and islet cell transplantation, allowing patients to recover and maintain a healthy life.
Alta Partners, SymBiosis Capital Management, Samsara BioCapital, Fan Ventures, Polaris Partners, HBM Partners, DaVita, Farallon Capital Management, T1D Fund, Osage University Partners, Eisai Innovation, Irving Investors, HBM Healthcare Investments, Codon Capital, Alexandria Venture Investments, The Invus Group, Altium Capital, E Squared Capital Management, Parkwood, Khosla Ventures, LifeSci Venture Partners, Catalio Capital Management, Lux Capital, Wellington Partners, Altium Capital Management.
Egenesis is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Egenesis stock. Depending on Egenesis’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Egenesis stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Egenesis stock in two ways. First, Egenesis employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Egenesis stock. Note that all transactions in Egenesis shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Egenesis stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Egenesis stock. Typically, shares of private companies like Egenesis are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Sep 2024, Egenesis is reported to have closed an equity financing in which the investors valued the company at $333M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Egenesis shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Egenesis is not currently publicly traded, it does not have a ticker symbol.
Egenesis has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Egenesis is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Egenesis shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.